Ratings Recordati

Equities

REC

IT0003828271

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-04-24 am EDT			5-day change	1st Jan Change
49.98 ^EUR	0.00%		+2.13%	+2.36%

Apr. 24	Global markets live: Heineken, AT&T Hasbro, Visa, Boeing...
Apr. 24	CVC Said Mulling Options for Majority Stake in Recordati	MT

Summary

According to Refinitiv, the company's ESG score for its industry is good.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company benefits from high valuations in earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
RECORDATI	+2.36%	11.58B	A-
ELI LILLY AND COMPANY	+25.61%	672B	C+
NOVO NORDISK A/S	+25.87%	570B	B
JOHNSON & JOHNSON	-5.24%	360B	C+
MERCK & CO., INC.	+16.49%	321B	B-
ABBVIE INC.	+8.28%	300B	C+
ASTRAZENECA PLC	+7.09%	217B	B+
ROCHE HOLDING AG	-9.12%	204B	A+
NOVARTIS AG	+5.01%	199B	B-
PFIZER, INC.	-8.75%	149B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes